Pacira reported second-quarter 2026 adjusted earnings of 73 cents per share, beating the Zacks Consensus Estimate of 64 cents, while revenues rose 6.2% to $192.4 million, also above expectations. The company lowered its full-year 2026 total revenue guidance to $735-$760 million from $745-$770 million, reflecting the divestiture of iovera to Zimmer Biomet, which closed on July 31. Exparel net product sales grew 3% to $147.8 million, and the company maintained its Exparel sales outlook of $600-$620 million. Shares have gained 6.9% since the earnings report, outperforming the S&P 500, but estimates have trended downward, and Pacira holds a Zacks Rank #3 (Hold).
Pacira BioSciences, Inc.Pacira beat Q2 EPS and revenue estimates but cut its full-year 2026 revenue guidance due to the iovera divestiture.
AstraZeneca PLC
Zimmer Biomet Holdings Inc